Investigational drug · Phase 2
KT-621
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Eosinophilic Asthma, Atopic Dermatitis, Asthma (Diagnosis).
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
6
Any phase or sponsor naming "KT-621"
First trial start
2025
Nov 24, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KT-621", any sponsor or status.
Conditions studied
As listed on its trial records.
- Eosinophilic Asthma
- Atopic Dermatitis
- Asthma (Diagnosis)
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Asthma · Immunology and inflammation · Respiratory · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "KT-621" as an intervention, largest first.
Kymera Therapeutics, Inc.Industry
NCT07677059 · 264 participants (planned) · Start Jun 25, 2026 · Primary completion Dec 2028
Drug: KT-621 · For: Asthma (Diagnosis)
Sites: Miami, Florida; Tampa, Florida; Dallas, Texas · 7 sites in all
- A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic AsthmaPivotal-lookingRecruiting
Kymera Therapeutics, Inc.Industry
NCT07323654 · 264 participants (planned) · Start Jan 28, 2026 · Primary completion Dec 2027
Drug: KT-621 · For: Eosinophilic Asthma
Sites: Lancaster, California; Long Beach, California; Northridge, California · 81 sites in all
- A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic DermatitisPivotal-lookingActive, not recruiting
Kymera Therapeutics, Inc.Industry
NCT07217015 · 200 participants (planned) · Start Nov 24, 2025 · Primary completion Jun 2027
Drug: KT-621 · For: Atopic Dermatitis
Sites: Birmingham, Alabama; North Little Rock, Arkansas; Los Angeles, California · 61 sites in all
- First-in-human Study of Orally Administered KT-621 in Healthy Adult ParticipantsPivotal-lookingCompleted
Kymera Therapeutics, Inc.Industry
NCT06673667 · 118 participants · Start Oct 22, 2024 · Primary completion Apr 23, 2025
Drug: KT-621; Placebo · For: Healthy Participants Study
Sites: Phoenix, Arizona; Lincoln, Nebraska
Kymera Therapeutics, Inc.Industry
NCT07823205 · 54 participants (planned) · Start Oct 5, 2026 · Primary completion Apr 2027
Drug: KT-621; KT-621 and 1 more · For: Healthy Participants
Sites: Lincoln, Nebraska
Kymera Therapeutics, Inc.Industry
NCT06945458 · 22 participants · Start Apr 17, 2025 · Primary completion Nov 10, 2025
Drug: KT-621 · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Fountain Valley, California; Santa Monica, California · 12 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Selective Targeting of STAT6: Recent Advances and Future Perspectives.
Liu H, Ma F, Wang Z, et al. · Med Res Rev 2026
Also in development for Eosinophilic Asthma
- Dexpramipexole DihydrochloridePhase 32 trials
Areteia Therapeutics · Chronic Obstructive Pulmonary Disease, Eosinophilic Asthma, Asthma; Eosinophilic
- AD17002LThPhase 22 trials
Advagene Biopharma Co. Ltd. · Eosinophilic Asthma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.